MedTrace Logo

Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss

NCT00400387 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 449

Last updated 2014-09-17

No results posted yet for this study

Summary

With this clinical trial the investigators will analyze whether the rate of pregnancy losses before the 24th week of gestation can be reduced by dalteparin treatment in habitual aborters.

Conditions

  • Abortion, Habitual

Interventions

DRUG

Fragmin P Forte (dalteparin sodium)

subcutaneous injection, once daily supported by multivitamine supplement and close monitoring

DIETARY_SUPPLEMENT

Multivitamin supplement

general pregnancy support by multivitamin supplementation and close monitoring

Sponsors & Collaborators

  • University of Jena

    lead OTHER

Principal Investigators

  • Ekkehard Schleussner, Prof. Dr. · University of Jena, Hospital for gynaecology and obstetrics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400387 on ClinicalTrials.gov